ROME—Co-morbidities and cytogenetic markers in older patients with chronic lymphocytic leukaemia can be used as an accurate guide to selecting therapy rather than using age cut-offs, according to Clem
Clemens Wendtner
ROME—Co-morbidities and cytogenetic markers in older patients with chronic lymphocytic leukaemia can be used as an accurate guide to selecting therapy rather than using age cut-offs, according to Clemens Wendtner, Professor of Medicine and Research Director of the Laboratory of Immunotherapy at the University of Cologne, Germany, who addressed the European Expert Forum on Blood Cancer in the Elderly in Rome. He tells ecancer radio about the potential for treating many fit older patients with the most effective regimens rather than consigning them to older alternatives.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110327ClemensWendtnerPODCASTLoRes.mp3]